Inhaled treatment for migraine on the cards

Published: 15-Jun-2002
Regulatory


Bradford Particle Design (bpd), the wholly owned subsidiary of Inhale Therapeutic Systems, has signed two new contracts: one with Sheffield Pharmaceuticals to develop a new inhalable migraine drug, dihydroorgotamine (DHE); and the other with Johnson & Johnson to investigate the application of bpd's supercritical technology to chemical manufacturing.

bpd's unique SEDS process uses supercritical fluids – gases at elevated temperatures and pressures – to control the formation of powder particles for the pharmaceutical industry. SEDS claims to offer the prospect of better performing drugs, shorter product development times, reduced risk of product recalls due to instability, and lower manufacturing costs. The process generates particles correctly the first time and ensures batch-to-batch consistency.

Sheffield will combine SEDS technology with its proprietary drug delivery technologies to develop systemically acting DHE administered through the pulmonary route. The company will study its use in more serious forms of migraine where DHE administered by injection is often used to relieve symptoms.

Under the terms of the agreement, Inhale will supply the particle engineering technology and receive r&d funding, milestone payments, and royalties upon commercialisation. Inhale will produce DHE particles at its plant in Bradford for clinical development and commercial sale.

In a separate agreement with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), bpd will investigate the application of its supercritical fluids technology to chemical manufacturing. Inhale will retain the rights to develop and market the new technology for broad usage.

Ajit Gill, president and ceo of Inhale, said: 'The extension of our relationship with J&JPRD demonstrates that our strategy to provide a range of drug-delivery solutions to the pharmaceutical industry, for different types of drugs and delivery routes, through various particle formation technologies, is well under way.' The collaboration between Inhale and J&JPRD follows a recent agreement in the area of respiratory delivery of particulate pharmaceuticals.

See more

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

Read more
New SOLAR CEMNEX analyser offers advanced compliance and connectivity features

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision

Partnership delivers compliance confidence, efficiency gains and reduced waste
Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Subscribe now